Stock Showing Surging Activity: Heat Biologics, Inc. (NASDAQ:HTBX)
By Alvin Buchanan -
December 5, 2016


Heat Biologics, Inc. (NASDAQ:HTBX) belonging to the Medical sector has surged 20.39% and closed its last trading session at $1.24.

The company reported its EPS on 11/11/2016. Currently, the stock has a 1 Year Price Target of $4.5.

The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.

Heat Biologics, Inc. on 11/11/2016 reported its EPS as $-0.08 with the analysts projecting the EPS of the stock as $-0.15. The company beat the analyst EPS Estimate with the difference of $0.07. This shows a surprise factor of 46.7%.

Many analysts have provided their estimated foresights on Heat Biologics, Inc. Earnings, with 2 analysts believing the company would generate an Average Estimate of $-0.1. Whereas they predicted High and Low Earnings Estimate as $-0.07 and $-0.12 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.78.

The Company got Initiated by ROTH Capital on 20-Jun-16 to Buy.

Insider Trades for Heat Biologics, Inc. show that the latest trade was made on 22 Mar 2016 where Kharitonov Michael, the Director completed a transaction type “Buy” in which 900000 shares were traded at a price of $0.75.



2 analysts projected Price Targets for Heat Biologics, Inc.. The analysts believe that the company stock price could grow as high as $7. The Low Price target projection by analysts is $2 and the Mean Price Target is $4.5.

Heat Biologics, Inc. (NASDAQ:HTBX) has the market capitalization of $29.6 Million. The company rocked its 52-Week High of $4.71 on Jan 6, 2016 and touched its 52-Week Low of $0.4 on May 13, 2016. The stock has Return on Assets (ROA) of -140.5 percent. Return on Equity (ROE) stands at -316% and Return on Investment (ROI) of 0 percent.

The stock is currently showing YTD performance of -49.18 Percent. The company has Beta Value of 0.58 and ATR value of 0.41. The Weekly and Monthly Volatility stands at 29.07% and 18.10%.

Company profile:

Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company’s products under development include HS-110 for the treatment of non-small cell lung cancer, HS-410 for the bladder cancer treatment, HS-310 to treat ovarian cancer and HS-510 for treating triple negative breast cancer. Heat Biologics, Inc. is based in Chapel Hill, North Carolina.